Member of the CEME Group

" VÊPRES managed the complexity of the project perfectly."

A two-storey, almost 600 m² project, incorporating all grades (A, B, C and D) of the pharmaceutical GMP standard. A new production line built on a site with multiple constraints.

Portrait of Gaël LE SAUX, Director of Adragos Pharma's French site.

Gaël LE SAUX, Director of ADAGROS PHARMA's French site.
Photo: Samuel MORAUD.

What does ADRAGOS PHARMA do?

Gaël LE SAUX: We 're what's known as a CDMO (Contract Development Manufacturing Organisations), a subcontractor to the pharmaceutical industry whose role is to manufacture and package medicines. At our Livron (Drôme) site, we have two specialties: the manufacture of sterile injectable glass ampoules and suppositories. We have some fifty customers covering a wide spectrum of therapeutic activities, including cardiology, anesthesia, neurology and many others.

Why did you choose VÊPRES ?

GLS: As part of our development and ADRAGOS PHARMA's ambitions, we needed a new production line to fill ampoules, including a new preparation unit for solutions. With demand growing in our sector, we needed capacity. Today, we have production volumes of 30 million suppositories and 125 million ampoules, which will continue to grow in the coming years. As far as ampoule production is concerned, this will make us a major player in the sector.

What equipment has been installed?

GLS: This is an overall project covering almost 600 m² spread over two levels, and incorporating all the grades (A, B, C and D) of the pharmaceutical GMP standards. We have a level dedicated to preparation, with manufacturing and storage tanks, a floor with multiple workshops (washer, steamer, etc.) and everything that makes up the specific features of a pharmaceutical production line (airlocks, pass-throughs, corridors, etc.). The layout of cleanroom, with its infrastructure and equipment, is a success. What's more, VÊPRES carried out the work under difficult conditions.

What were the project's constraints?

GLS: I think the main challenge was the site itself. It dates back to 1918 and presents architectural, structural and space constraints. VÊPRES rose to the challenge. They adapted to the existing site, with a very restricted storage and worksite environment. They had to work on the site's structure (completely rebuilding the shell and slab, raising the roof on the upper floor) to be able to fit out cleanroom. They then carried out the work in parallel with our business, which continued uninterrupted throughout the year the project lasted. VÊPRES perfectly managed the complexity of the project.

What are the regulatory requirements?

GLS: The pharmaceutical sector is evolving very rapidly in terms of regulations, particularly quality standards for the manufacture of sterile drugs, with constraints on machines, the environment and practices guided in particular by Annex 1 of the GMP (Good Manufacturing Practices), which has introduced new requirements with regulatory changes in production and the environment.

Why did you choose VÊPRES ?

GLS: VÊPRES was chosen following positive feedback fromExcelvision (FAREVA) and the quality of discussions during the tender process. Their reputation, contact and level of commitment all played a part.

What do you retain from this operation?

GLS: I've always found the teams and people to be top-quality, hard-working and easy to communicate with. They're responsive and good listeners. And that's very pleasing when you're doing major, long-term work.

For ADRAGOS PHARMA, VÊPRES carried out a complex project in a constrained environment.

Project for ADRAGOS PHARMA

A global project of almost 600 m² integrating all the grades (A, B, C and D) of the pharmaceutical reference framework of Good Manufacturing Practices. (...)

Mastering constraints

Read Gaël LE SAUX's testimonial following the intervention of VÊPRES teams at ADRAGOS PHARMA's French site. For one year, the creation of a new production line required major works on a very old site with numerous space constraints, without interrupting production.

ADRAGOS PHARMA
ADRAGOS PHARMA

ADRAGOS PHARMA

Construction of a new production line for ADRAGOS PHARMA, in a constrained environment and without interruption of activity.

ADRAGOS PHARMA
ELOGEN
ELOGEN

ELOGEN

Three projects with a total surface area of 300 m², including an assembly line and a laboratory, have been completed for ELOGEN, a specialist in electrolyzers producing green hydrogen.

ELOGEN
BECTON DICKINSON
BECTON DICKINSON

BECTON DICKINSON

For Becton Dickinson, VÊPRES has created a QCL laboratory in an existing building, on an area of 600 m².

BECTON DICKINSON
LUMIBIRD - QUANTEL
LUMIBIRD - QUANTEL

LUMIBIRD - QUANTEL

The construction of a cleanroom ISO 8 of 640 m² was completed in less than 8 months for LUMIBIRD.

LUMIBIRD - QUANTEL
Laboratoires URIAGE
Laboratoires URIAGE

Laboratoires URIAGE

A large-scale project, covering 1,200 m², was carried out in a very short time by VÊPRES to set up packaging rooms for URIAGE's laboratories.

Laboratoires URIAGE